In previous reports, early ALK positivity of the tumor was associated with a poor outcome in lung adenocarcinoma.29–31 Therefore, it is important to treat with adjuvant-targeted therapy or pemetrexed-based adjuvant chemotherapy for resected early stage lung cancer with ALK or fusion mutation.32 This evidence concerns the gene ALK and lung adenocarcinoma.